Free Trial
NASDAQ:ELVN

Enliven Therapeutics Q1 2025 Earnings Report

Enliven Therapeutics logo
$17.69 -0.21 (-1.17%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$17.78 +0.09 (+0.54%)
As of 08/8/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enliven Therapeutics EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

Enliven Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enliven Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Enliven Therapeutics' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Friday, August 15, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Enliven Therapeutics Earnings Headlines

Enliven Therapeutics, Inc. (ELVN) - Yahoo Finance
One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
See More Enliven Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enliven Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enliven Therapeutics and other key companies, straight to your email.

About Enliven Therapeutics

Enliven Therapeutics (NASDAQ:ELVN), a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

View Enliven Therapeutics Profile

More Earnings Resources from MarketBeat